Equities

Krsnaa Diagnostics Ltd

KRSNAA:NSI

Krsnaa Diagnostics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (INR)911.55
  • Today's Change11.55 / 1.28%
  • Shares traded69.40k
  • 1 Year change+43.55%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Krsnaa Diagnostics Limited is an India-based company primarily engaged in the business of providing diagnostic services primarily in relation to pathology investigation, radiology investigation and tele reporting. The Company’s service offerings cover pathology, X-Ray, and computed tomography (CT) scan, magnetic resonance imaging (MRI), USG, tele-radiology, tele-pathology, and other diagnostic services. Its laboratory services span a diverse range of investigations, ranging from routine to highly specialized tests. Its teleradiology services enable radiologists to offer treatment remotely. Teleradiology involves transmitting radiological images, such as CT scans, digitized X-rays, MRIs and ultrasounds between different locations. It offers various health packages in addition to its Ayaksham package. It provides diagnostic testing packages for diabetes, heart health, liver health, kidney health, thyroid, fatigue, cancer, senior citizen care, bone health, infection screening, and more.

  • Revenue in INR (TTM)6.81bn
  • Net income in INR692.16m
  • Incorporated2010
  • Employees3.70k
  • Location
    Krsnaa Diagnostics LtdS.No.243,A-Hissa No.6/6 CTS No.4519Near Mayur Trade Centre, ChinchwadPune 411 019IndiaIND
  • Phone+91 2 027350025
  • Websitehttps://krsnaadiagnostics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Max India Ltd1.55bn-891.67m10.61bn20.00--2.38--6.85-20.43-20.4335.48103.040.2262.1130.1577,478,550.00-13.01---16.74--77.9365.15-57.54-24.361.98-24.450.118---12.642.82-442.97------
GPT Healthcare Ltd-100.00bn-100.00bn13.42bn1.89k--------------------------10.18--12.97--77.99--10.33------0.0010.8518.4222.4626.15-5.19--
Shalby Ltd10.07bn547.21m22.59bn2.85k41.892.2419.922.245.035.0392.6093.850.66412.366.493,529,299.003.444.824.385.5343.5063.925.188.200.8933.560.31419.1816.0315.1024.1921.578.3919.14
Krsnaa Diagnostics Ltd6.81bn692.16m29.04bn3.70k43.033.4519.084.2620.9020.90205.92260.380.57434.923.391,841,019.005.846.727.918.5975.7582.0010.1611.741.013.890.2045--27.2024.25-8.49--14.21--
Artemis Medicare Services Ltd8.92bn559.89m37.10bn1.99k68.28--37.914.163.953.9563.08--------4,481,337.00------------6.274.59--3.04--4.1919.149.9627.3219.12----
Indraprastha Medical Corporation Ltd13.19bn1.48bn37.90bn2.98k25.657.2319.922.8716.1216.12143.8857.211.7970.8118.384,430,198.0020.0512.7427.7917.0457.5357.3211.216.732.0332.690.058833.0913.299.5743.8934.2632.3422.98
Medi Assist Healthcare Services Ltd6.62bn702.67m41.71bn3.82k59.93--34.486.309.899.5693.56--------1,734,239.00--9.27--16.33--99.1510.9713.18--25.98--13.7125.7018.05-8.3315.93-2.61--
Thyrocare Technologies Ltd6.23bn839.70m50.12bn1.69k60.1310.2637.618.0415.7415.74116.6892.191.054.7512.073,681,394.0013.8318.1716.0720.9770.8969.6613.2019.562.12--0.036683.578.587.269.94-3.638.88-2.09
Yatharth Hospital & Trauma Cre Srvcs Ltd7.74bn1.29bn50.23bn2.19k37.895.3929.186.4915.4415.4492.57108.590.795215.713.583,542,136.0013.2711.2714.1013.7379.4477.7616.6812.307.2086.400.08820.0028.8845.7874.0695.813.69--
Healthcare Global Enterprises Ltd20.39bn570.45m64.20bn6.15k113.677.4525.883.154.054.05145.2461.830.743520.915.923,316,034.002.23-2.263.09-3.0553.2253.783.00-3.500.84191.370.6324--12.8014.3564.08---0.3308--
Data as of Nov 14 2024. Currency figures normalised to Krsnaa Diagnostics Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

14.02%Per cent of shares held by top holders
HolderShares% Held
Tata Asset Management Pvt Ltd.as of 31 Oct 20242.55m7.89%
HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2024664.76k2.06%
ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024565.20k1.75%
Bandhan AMC Ltd.as of 30 Sep 2024431.78k1.34%
Dimensional Fund Advisors LPas of 03 Oct 2024122.09k0.38%
Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 2024100.00k0.31%
Mellon Investments Corp.as of 03 Oct 202458.59k0.18%
Dimensional Fund Advisors Ltd.as of 31 Aug 202419.28k0.06%
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 202410.96k0.03%
SSgA Funds Management, Inc.as of 03 Oct 20248.34k0.03%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.